246 related articles for article (PubMed ID: 29684820)
1. Increased oxidative stress mediates the antitumor effect of PARP inhibition in ovarian cancer.
Hou D; Liu Z; Xu X; Liu Q; Zhang X; Kong B; Wei JJ; Gong Y; Shao C
Redox Biol; 2018 Jul; 17():99-111. PubMed ID: 29684820
[TBL] [Abstract][Full Text] [Related]
2. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Henning RJ; Bourgeois M; Harbison RD
Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
[TBL] [Abstract][Full Text] [Related]
3. Berberine induces oxidative DNA damage and impairs homologous recombination repair in ovarian cancer cells to confer increased sensitivity to PARP inhibition.
Hou D; Xu G; Zhang C; Li B; Qin J; Hao X; Liu Q; Zhang X; Liu J; Wei J; Gong Y; Liu Z; Shao C
Cell Death Dis; 2017 Oct; 8(10):e3070. PubMed ID: 28981112
[TBL] [Abstract][Full Text] [Related]
4. Poly (ADP) ribose polymerase inhibition: A potential treatment of malignant peripheral nerve sheath tumor.
Kivlin CM; Watson KL; Al Sannaa GA; Belousov R; Ingram DR; Huang KL; May CD; Bolshakov S; Landers SM; Kalam AA; Slopis JM; McCutcheon IE; Pollock RE; Lev D; Lazar AJ; Torres KE
Cancer Biol Ther; 2016; 17(2):129-38. PubMed ID: 26650448
[TBL] [Abstract][Full Text] [Related]
5. 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.
Hurley RM; Wahner Hendrickson AE; Visscher DW; Ansell P; Harrell MI; Wagner JM; Negron V; Goergen KM; Maurer MJ; Oberg AL; Meng XW; Flatten KS; De Jonge MJA; Van Herpen CD; Gietema JA; Koornstra RHT; Jager A; den Hollander MW; Dudley M; Shepherd SP; Swisher EM; Kaufmann SH
Gynecol Oncol; 2019 Apr; 153(1):127-134. PubMed ID: 30686551
[TBL] [Abstract][Full Text] [Related]
6. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of APE1 potentiates breast cancer cells to olaparib by inhibiting PARP-1 expression.
Ma X; Dang C; Min W; Diao Y; Hui W; Wang X; Dai Z; Wang X; Kang H
Breast Cancer Res Treat; 2019 Jul; 176(1):109-117. PubMed ID: 30989461
[TBL] [Abstract][Full Text] [Related]
8. Radiosensitization by PARP Inhibition in DNA Repair Proficient and Deficient Tumor Cells: Proliferative Recovery in Senescent Cells.
Alotaibi M; Sharma K; Saleh T; Povirk LF; Hendrickson EA; Gewirtz DA
Radiat Res; 2016 Mar; 185(3):229-45. PubMed ID: 26934368
[TBL] [Abstract][Full Text] [Related]
9. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) induces oxidative stress, DNA strand breaks, and poly(ADP-ribose) polymerase-1 activation in human breast carcinoma cell lines.
Lin PH; Lin CH; Huang CC; Chuang MC; Lin P
Toxicol Lett; 2007 Aug; 172(3):146-58. PubMed ID: 17669606
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of PARP1 transcription by CDK4/6 inhibitors sensitizes human lung cancer cells to anticancer drug-induced death by impairing OGG1-dependent base excision repair.
Tempka D; Tokarz P; Chmielewska K; Kluska M; Pietrzak J; Rygielska Ż; Virág L; Robaszkiewicz A
Redox Biol; 2018 May; 15():316-326. PubMed ID: 29306194
[TBL] [Abstract][Full Text] [Related]
11. Radiosensitization by the PARP inhibitor olaparib in BRCA1-proficient and deficient high-grade serous ovarian carcinomas.
Bi Y; Verginadis II; Dey S; Lin L; Guo L; Zheng Y; Koumenis C
Gynecol Oncol; 2018 Sep; 150(3):534-544. PubMed ID: 30025822
[TBL] [Abstract][Full Text] [Related]
12. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.
Du Y; Yamaguchi H; Wei Y; Hsu JL; Wang HL; Hsu YH; Lin WC; Yu WH; Leonard PG; Lee GR; Chen MK; Nakai K; Hsu MC; Chen CT; Sun Y; Wu Y; Chang WC; Huang WC; Liu CL; Chang YC; Chen CH; Park M; Jones P; Hortobagyi GN; Hung MC
Nat Med; 2016 Feb; 22(2):194-201. PubMed ID: 26779812
[TBL] [Abstract][Full Text] [Related]
13. The Poly(ADP-Ribose)Polymerase-1 Inhibitor 1,5-Isoquinolinediol Attenuate Diabetes-Induced NADPH Oxidase-Derived Oxidative Stress in Retina.
Mohammad G; Alrashed SH; Almater AI; Siddiquei MM; Abu El-Asrar AM
J Ocul Pharmacol Ther; 2018 Sep; 34(7):512-520. PubMed ID: 29912609
[TBL] [Abstract][Full Text] [Related]
14. PARP1-siRNA suppresses human prostate cancer cell growth and progression.
Lai Y; Kong Z; Zeng T; Xu S; Duan X; Li S; Cai C; Zhao Z; Wu W
Oncol Rep; 2018 Apr; 39(4):1901-1909. PubMed ID: 29393407
[TBL] [Abstract][Full Text] [Related]
15. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
Liu FW; Tewari KS
Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
[TBL] [Abstract][Full Text] [Related]
16. [PARP inhibitors--theoretical basis and clinical application].
Dębska S; Kubicka J; Czyżykowski R; Habib M; Potemski P
Postepy Hig Med Dosw (Online); 2012 May; 66():311-21. PubMed ID: 22706117
[TBL] [Abstract][Full Text] [Related]
17. Phosphatase 1 Nuclear Targeting Subunit Mediates Recruitment and Function of Poly (ADP-Ribose) Polymerase 1 in DNA Repair.
Wang F; Zhu S; Fisher LA; Wang L; Eurek NJ; Wahl JK; Lan L; Peng A
Cancer Res; 2019 May; 79(10):2526-2535. PubMed ID: 30733193
[TBL] [Abstract][Full Text] [Related]
18. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
[TBL] [Abstract][Full Text] [Related]
19. Synthetic lethality between BRCA1 deficiency and poly(ADP-ribose) polymerase inhibition is modulated by processing of endogenous oxidative DNA damage.
Giovannini S; Weller MC; Repmann S; Moch H; Jiricny J
Nucleic Acids Res; 2019 Sep; 47(17):9132-9143. PubMed ID: 31329989
[TBL] [Abstract][Full Text] [Related]
20. Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function.
Gui B; Gui F; Takai T; Feng C; Bai X; Fazli L; Dong X; Liu S; Zhang X; Zhang W; Kibel AS; Jia L
Proc Natl Acad Sci U S A; 2019 Jul; 116(29):14573-14582. PubMed ID: 31266892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
